title: [Pathogenesis, diagnosis and treatment of hepatic encephalopathies in patients with liver cirrhosis].
abstract: The data on the positive experience with hepatic encephalopathy in patients with cirrhosis liver L-ornithine-L-aspartate (drug larnamyn), the effectiveness of which is provided by its components (amino acids, ornithine and aspartate) which improve metabolism, ammonia detoxification mechanism, production of energy in the Krebs cycle, promote restoration of the cell membrane, and carried out anti-inflammatory and detoxicative effect.
authors.forename: V O
authors.initials: VO
authors.lastname: Moĭseienko
authors.forename: E H
authors.initials: EH
authors.lastname: Manzhaliĭ
authors.forename: O S
authors.initials: OS
authors.lastname: Solonovych
authors.forename: T D
authors.initials: TD
authors.lastname: Nykula
mesh_terms: D000328:Adult; D000368:Aged; D000641:Ammonia / Q000378:metabolism; D002952:Citric Acid Cycle / Q000187:drug effects; D004151:Dipeptides / Q000627:therapeutic use*; D018913:Event-Related Potentials, P300 / Q000187:drug effects; D005260:Female; D006501:Hepatic Encephalopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020011:Protective Agents / Q000627:therapeutic use*; D012720:Severity of Illness Index
chemical_list: D004151:Dipeptides; D020011:Protective Agents; D000641:Ammonia; C002939:ornithylaspartate